Epcoritamab regimen active in untreated follicular lymphoma

ByAshley Killen

ByLori A. Leslie, MD

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — The addition of subcutaneous epcoritamab to rituximab and lenalidomide demonstrated encouraging efficacy as first-line treatment for follicular lymphoma, according to results presented at ASH Annual Meeting and Exposition.

The combination also exhibited a manageable safety profile, initial findings from a phase 1/phase 2 trial showed.

Healio spoke with researcher Lori A. Leslie, MD, director of the indolent lymphoma and chronic lymphocytic leukemia research programs at Hackensack Meridian John Theurer Cancer Center, about the study results and their potential implications.

Published by:

Sources/Disclosures

Collapse

Source:

Scordo M, et al. Abstract 657. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Disclosures: Leslie reports consulting/advisory roles with, travel support from, speakers bureau roles with or other relationships with AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Eli Lilly, Epizyme, Janssen, Karyopharm Therapeutics, Kite/Gilead, Merck, Pharmacyclics, Seagen and TG Therapeutics.

ASH Annual Meeting and Exposition

Read more

Epcoritamab regimen active in untreated follicular lymphoma

Related Content